NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide
NHS England is establishing a national framework for supply of three specialist medicines: lenalidomide, pomalidomide, and thalidomide. The framework runs two years from June 2026, covering three regional NHS procurement hubs, with optional extension to 48 months total.
- Closed9 March 2026
- Value£34m
- Per lot£11m across 3 lots
- BuyerNHS England
- CategoryHealth & medical
- RegionUK-wide
You'll want to look if you are a pharmaceutical wholesaler or manufacturer licensed to distribute lenalidomide, pomalidomide, or thalidomide in the UK
Might not suit a small firm
- the contract itself is a large one
- it needs coverage across the whole UK
Possible incumbent
Multiple suppliers held the previous Wave 15c generic pharmaceuticals framework; specialist products like these were previously awarded to Mercury Pharmaceuticals, Orifarm UK, and Janssen Cilag in separate 2025 frameworks. Inferred from prior awards to this buyer, not confirmed.